Community treatment of HIV-1: initial stage and asymptotic dynamics.

Treatment with antiviral drugs (zidovudine and ddI) has been reported to delay progression to AIDS, and may even possibly lower the infectiousness of the infectives. However, its effect on the community level is still uncertain. The latter is important since a successful community treatment program must meet both public health and individual health goals. Our study will focus on the effect of a community-wide treatment program initiated at the early stages of the disease as well as the long-term effect of the program. Using a simple mathematical model, we demonstrate that a community-wide treatment program could be instrumental in decreasing HIV incidence rate and eradicating the disease in the future if certain conditions on the parameters are met. On the other hand, when the above mentioned conditions on the parameters are not satisfied, we show that even if the treatment does improve survival in AIDS patients and decrease the rate at which HIV infection spreads in the community, it is still possible for the treatment program to have an adverse effect on the spread of AIDS in the population in the long run. Hence, a public health policy maker must exercise caution in order to design an effective treatment program for HIV/AIDS.

[1]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[2]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[3]  Robert T. Schooley,et al.  Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex , 1989 .

[4]  R. M. May,et al.  Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1 , 1991, Nature.

[5]  Roy M. Anderson,et al.  Mathematical Models and the Design of Public Health Policy: Hiv and Antiviral Therapy , 1993, SIAM Rev..

[6]  S W Lagakos,et al.  Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection , 1990 .

[7]  V L Murphy,et al.  Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy. , 1991, The Journal of infectious diseases.

[8]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[9]  D. Mack,et al.  Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT). , 1988, Annals of internal medicine.

[10]  Ying-Hen Hsieh,et al.  Modelling the effect of treatment and behavioral change in HIV transmission dynamics , 1994, Journal of mathematical biology.

[11]  A. J. Hall Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .

[12]  M A Fischl,et al.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.